Active Ingredient History
Perampanel (trade name Fycompa) is an antiepileptic drug developed by Eisai Co. that acts as a selective non-competitive antagonist of AMPA receptors, the major subtype of ionotropic glutamate receptors. Although the mechanism of action through which perampanel exerts its antiepileptic effect has not been fully elucidated, this agent antagonizes the AMPA subtype of the excitatory glutamate receptor found on postsynaptic neurons in the central nervous system (CNS). This antagonistic action prevents AMPA receptor activation by glutamate and results in the inhibition of neuronal excitation, repetitive neuronal firing, and the stabilization of hyper-excited neural membranes. Glutamate, the primary excitatory neurotransmitter in the CNS, plays an important role in various neurological disorders caused by neuronal hyperexcitation. The drug is currently approved, for the control of partial-onset seizures, in those of both sexes who suffer from epilepsy and who are 12 years of age and older, by the Food and Drug Administration. Perampanel is also approved for the treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older. It is designated as a Schedule III controlled substance by the Drug Enforcement Administration. Perampanel has been studied in other clinical indications including Parkinson's disease. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Alcohol-Induced Disorders (Phase 1/Phase 2)
Alcoholism (Phase 2)
Amyotrophic Lateral Sclerosis (Phase 2)
Bipolar Disorder (Phase 2)
Brain Neoplasms (Phase 4)
Central Nervous System (Phase 2)
Depression (Phase 1)
Depressive Disorder (Phase 2)
Depressive Disorder, Major (Phase 2)
Diabetic Neuropathies (Phase 2/Phase 3)
Drug Resistant Epilepsy (Phase 4)
Electroencephalography (Phase 4)
Epilepsies, Partial (Phase 4)
Epilepsy ()
Essential Tremor (Phase 2)
General Surgery (Phase 1/Phase 2)
Glioma (Phase 4)
Healthy Volunteers (Phase 4)
Lennox Gastaut Syndrome (Phase 3)
Migraine Disorders (Phase 2)
Neuralgia (Phase 2/Phase 3)
Parkinson Disease (Phase 3)
Pediatrics (Phase 2)
Seizures (Phase 4)
Small Fiber Neuropathy (Phase 2)
Status Epilepticus (Phase 3)
Stress Disorders, Post-Traumatic (Phase 2)
Suicidal Ideation (Phase 2)
Torticollis (Phase 1/Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue